Head-To-Head Survey: Eiger Biopharmaceuticals (EIGR) and SenesTech (SNES)
Eiger Biopharmaceuticals (NASDAQ: EIGR) and SenesTech (NASDAQ:SNES) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Valuation and Earnings
This table compares Eiger Biopharmaceuticals and SenesTech’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eiger Biopharmaceuticals||N/A||N/A||-$47.08 million||($5.30)||-2.71|
Insider and Institutional Ownership
47.1% of Eiger Biopharmaceuticals shares are owned by institutional investors. Comparatively, 14.4% of SenesTech shares are owned by institutional investors. 28.8% of Eiger Biopharmaceuticals shares are owned by company insiders. Comparatively, 27.4% of SenesTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Eiger Biopharmaceuticals and SenesTech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Eiger Biopharmaceuticals and SenesTech, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eiger Biopharmaceuticals currently has a consensus price target of $32.86, indicating a potential upside of 128.97%. SenesTech has a consensus price target of $8.50, indicating a potential upside of 1,114.29%. Given SenesTech’s higher probable upside, analysts clearly believe SenesTech is more favorable than Eiger Biopharmaceuticals.
Eiger Biopharmaceuticals beats SenesTech on 6 of the 11 factors compared between the two stocks.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
SenesTech Company Profile
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.